PLX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of 10.9% beat Perspective Therapeutics's return on equity of --.

Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 773.49%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 453.22%. Given that Protalix BioTherapeutics has higher upside potential than Perspective Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Perspective Therapeutics.

Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Protalix BioTherapeutics's net income of -$3.6M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 41.50x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.33x versus 16.51x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -16566.39%. Protalix BioTherapeutics's return on equity of 10.9% beat Inovio Pharmaceuticals's return on equity of -119.02%.

Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 773.49%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.83 which suggests that it could grow by 307.99%. Given that Protalix BioTherapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Inovio Pharmaceuticals.

Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.401, suggesting its more volatile than the S&P 500 by 40.133%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Inovio Pharmaceuticals quarterly revenues of $117K. Protalix BioTherapeutics's net income of -$3.6M is higher than Inovio Pharmaceuticals's net income of -$19.4M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 41.50x while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.33x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -27.95%. Protalix BioTherapeutics's return on equity of 10.9% beat NexGel's return on equity of -63.18%.

Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 773.49%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 117.39%. Given that Protalix BioTherapeutics has higher upside potential than NexGel, analysts believe Protalix BioTherapeutics is more attractive than NexGel.

Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than NexGel quarterly revenues of $3M. Protalix BioTherapeutics's net income of -$3.6M is lower than NexGel's net income of -$850K. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 41.50x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.33x versus 2.07x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -309.84%. Protalix BioTherapeutics's return on equity of 10.9% beat Sangamo Therapeutics's return on equity of -217.48%.

Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 773.49%. On the other hand Sangamo Therapeutics has an analysts' consensus of $4.90 which suggests that it could grow by 965.22%. Given that Sangamo Therapeutics has higher upside potential than Protalix BioTherapeutics, analysts believe Sangamo Therapeutics is more attractive than Protalix BioTherapeutics.

Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.456, suggesting its more volatile than the S&P 500 by 45.634%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Sangamo Therapeutics quarterly revenues of $7.6M. Protalix BioTherapeutics's net income of -$3.6M is higher than Sangamo Therapeutics's net income of -$23.4M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 41.50x while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.33x versus 1.61x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.